Skip to main content
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1994 May;32(5):1357–1359. doi: 10.1128/jcm.32.5.1357-1359.1994

Significance of highly positive c22-3 "indeterminate" second-generation hepatitis C virus (HCV) recombinant immunoblot assay (RIBA) and resolution by third-generation HCV RIBA.

J M Pawlotsky 1, A Fleury 1, V Choukroun 1, L Deforges 1, F Roudot-Thoraval 1, P Aumont 1, J Duval 1, D Dhumeaux 1
PMCID: PMC263701  PMID: 7519631

Abstract

Second-generation recombinant immunoblot assay (RIBA) is widely used for the validation of anti-hepatitis C virus (HCV) antibody detection. The aims of this work were (i) to determine, in terms of liver disease and HCV replication, the significance of a peculiar "indeterminate" second-generation RIBA pattern characterized by the presence of high titers of antibodies directed to c22-3, a protein bearing core epitopes and (ii) to determine whether a more advanced version of the same strip assay, namely a third-generation RIBA, may solve the problem of such indeterminate patterns. Sixty patients for which c22-3 indeterminate second-generation RIBAs were highly positive were studied. Forty-two of them (70%) were immunocompromised. Serum transaminases were increased in 46 cases (77%), and HCV RNA was detected by PCR in 50 cases (83%). Third-generation RIBA remained highly positive c22 indeterminate for 9 patients (15%) but was positive for 51 (85%), mostly because of increased sensitivity for the detection of both anti-c100 and anti-c33c antibodies. These results suggest that third-generation RIBA may achieve resolution of most of these cases but that highly positive c22 indeterminate third-generation RIBA may persist when used with some patients with very low titers of anti-HCV nonstructural protein antibodies.

Full text

PDF
1357

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberti A., Morsica G., Chemello L., Cavalletto D., Noventa F., Pontisso P., Ruol A. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet. 1992 Sep 19;340(8821):697–698. doi: 10.1016/0140-6736(92)92234-7. [DOI] [PubMed] [Google Scholar]
  2. Allain J. P., Rankin A., Kuhns M. C., McNamara A. Clinical importance of HCV confirmatory testing in blood donors. Lancet. 1992 May 9;339(8802):1171–1172. doi: 10.1016/0140-6736(92)90772-u. [DOI] [PubMed] [Google Scholar]
  3. Follett E. A., Dow B. C., McOmish F., Yap P. L., Hughes W., Mitchell R., Simmonds P. HCV confirmatory testing of blood donors. Lancet. 1991 Oct 19;338(8773):1024–1024. doi: 10.1016/0140-6736(91)91891-w. [DOI] [PubMed] [Google Scholar]
  4. Gretch D., Lee W., Corey L. Use of aminotransferase, hepatitis C antibody, and hepatitis C polymerase chain reaction RNA assays to establish the diagnosis of hepatitis C virus infection in a diagnostic virology laboratory. J Clin Microbiol. 1992 Aug;30(8):2145–2149. doi: 10.1128/jcm.30.8.2145-2149.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Halfon P., Rousseau S., Tamalet C., Antoni M., Gerolami V., Levy M., Bourliere M., Planells R., Cartouzou G. Indeterminate second-generation hepatitis C recombinant immunoblot test: detection of hepatitis C virus infection by polymerase chain reaction. J Infect Dis. 1992 Aug;166(2):449–449. doi: 10.1093/infdis/166.2.449. [DOI] [PubMed] [Google Scholar]
  6. Lazizi Y., Elfassi E., Pillot J. Detection of hepatitis C virus sequences in sera with controversial serology by nested polymerase chain reaction. J Clin Microbiol. 1992 Apr;30(4):931–934. doi: 10.1128/jcm.30.4.931-934.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Li X. M., Reddy K. R., Jeffers L. J., Parker T., de Medina M., Schiff E. R. Indeterminate hepatitis C. Lancet. 1993 Mar 27;341(8848):835–835. doi: 10.1016/0140-6736(93)90616-o. [DOI] [PubMed] [Google Scholar]
  8. Pawlotsky J. M., Deforges L., Bretagne S., André C., Métreau J. M., Thiers V., Zafrani E. S., Goossens M., Duval J., Mavier J. P. Hepatitis C virus infection can mimic type 1 (antinuclear antibody positive) autoimmune chronic active hepatitis. Gut. 1993;34(2 Suppl):S66–S68. doi: 10.1136/gut.34.2_suppl.s66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Van der Poel C. L., Cuypers H. T., Reesink H. W., Weiner A. J., Quan S., Di Nello R., Van Boven J. J., Winkel I., Mulder-Folkerts D., Exel-Oehlers P. J. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet. 1991 Feb 9;337(8737):317–319. doi: 10.1016/0140-6736(91)90942-i. [DOI] [PubMed] [Google Scholar]
  10. Zaaijer H. L., Cuypers H. T., Reesink H. W., Winkel I. N., Gerken G., Lelie P. N. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet. 1993 Mar 20;341(8847):722–724. doi: 10.1016/0140-6736(93)90488-3. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES